The US pharmaceutical giant, Pfizer, has officially subjugated a fierce bidding war against Danish pharmaceutical rival Novo Nordisk for the acquisition of Metsera Inc., a biotech company spearheading the obesity treatment industry with its next-generation weight loss drugs, for a staggering amount of approximately $10 billion (USD) (Reuters). This move not only delineates Pfizer’s fervent medical ambitions but also forges Pfizer’s way into the lucrative anti-obesity and metabolic disease drug industry, even as Metsera’s drugs and treatments remain years from real-world testing and commercialisation.
In late September of 2025, Pfizer proclaimed its plans to buy Metsera for approximately $4.9 billion (USD) in order to diversify its dwindling product line after the revenue numbers from the COVID-19 vaccine started fading. However, the original deal did not hold its water for long, when Danish pharmaceutical, Novo Nordisk, countered the offer with a more lucrative one, thereby pushing the deal value close to $10 billion (USD). This ignited an intense battle between the two giants. Additionally, the US regulator, FTC, also raised antitrust concerns over Novo’s burgeoning dominance in the weight-loss drug market, thus favoring Pfizer. And, by the 8th of November 2025, Pfizer closed the deal with a sweetened bid of $86.25 per share, out of which $65.60 in cash plus bonuses predicated on the future performance of the company. This bold move sidelined Novo’s offer and led the Metsera’s board to recommend that its shareholders accept Pfizer’s deal.
For Pfizer, the acquisition of Metsera is a strategic move to regain relevance and lead the booming obesity-drug market, which is expected to reach $100 – $150 billion (USD) globally within a decade, as per various research forums (Morgan Stanley). The rationale behind this bold and extravagant move is clear: if Metsera’s drugs succeed, they could offer simpler doses and stronger results than currently available treatments in the market, putting Pfizer back on the leaderboard alongside other major players such as Eli Lilly and Novo Nordisk. On the other hand, for Novo Nordisk, losing the acquisition of Metsera marks a rare setback in its long-standing domination in the weight-loss drug market. Eventually, it was not the monetary aspect of the deal that withheld Novo but the scrutiny and involvement of the US regulators, who warned that Novo’s acquisition of Metsera would stifle the competition in the already saturated market.
To recapitulate, this riveting bidding war underscored a broader trend that weight-loss medicine has become the new biotech gold rush, where investors are willing to pour billions of dollars into the next generation of obesity and metabolic treatments. With Pfizer’s Metsera deal setting the theme for the upcoming decade, the realistic payout of this $10 billion (USD) wager will be revealed in the years ahead. For now, one thing is certain that Pfizer is not withholding any punches to fortify its market standing for the next era of growth.
Fatehbir Singh Sohu 